The burden of skin diseases: 2004 : A joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology - 09/08/11

Doi : 10.1016/j.jaad.2006.05.048

David R. Bickers, MD ^a,^⁎, Henry W. Lim, MD ^b, David Margolis, MD, PhD ^c, Martin A. Weinstock, MD, PhD ^d, Clifford Goodman, PhD ^e, Eric Faulkner, MPH ^f, Ciara Gould, MSPH ^g, Eric Gemmen, MA ^h, Tim Dall, MS ^e
^a From the Department of Dermatology, Columbia University College of Physicians and Surgeons, New York
^b Department of Dermatology, Henry Ford Hospital, Detroit
^c Departments of Dermatology and Biostatistics and Epidemiology, University of Pennsylvania
^d Dermatoepidemiology Unit, Department of Veterans Affairs Medical Center Providence, Department of Dermatology, Rhode Island Hospital and Brown University, and Department of Community Health, Brown University
^e The Lewin Group, Falls Church
^f The Littell Group, Woodstock
^g United Network for Organ Sharing, Richmond
^h Quintiles Strategic Research Services, Falls Church

Reprint requests: David R. Bickers, MD, Society for Investigative Dermatology, 820 W Superior Ave, Seventh Floor, Cleveland, OH 44113.

New York, New York; Detroit, Michigan; Philadelphia, Pennsylvania; Providence, Rhode Island; and Falls Church, Woodstock, and Richmond, Virginia

Abstract

Skin disease is one of the top 15 groups of medical conditions for which prevalence and health care spending increased the most between 1987 and 2000, with approximately 1 of 3 people in the United States with a skin disease at any given time. Even so, a national data profile on skin disease has not been conducted since the late 1970s. This study closes the gap by estimating the prevalence, economic burden, and impact on quality of life for 22 leading categories of skin disease. The estimated annual cost of skin disease in 2004 was $39.3 billion, including $29.1 billion in direct medical costs (costs of health services and products) and $10.2 billion in lost productivity costs (defined as costs related to consumption of medical care, costs associated with impaired ability to work, and lost future earning potential because of premature death). Based on a methodology of willingness to pay for symptom relief, the additional economic burden of skin disease on quality of life amounted to an estimated $56.2 billion. Including the economic burden on quality of life, the total economic burden of skin disease to the US public in 2004 was approximately $96 billion.

Le texte complet de cet article est disponible en PDF.

Abbreviations used : DLQI, ED, NCI, NHAMCS, NHIS, NIH, NIS, OPD, OTC, SAF